Drug Profile


Alternative Names: GABRA5 negative allosteric modulator (NAM) - Roche; RG-1662; RO5186582

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Roche
  • Developer Chugai Pharmaceutical; Roche
  • Class Antidementias; Oxazoles; Pyridines; Small molecules; Thiamorpholines
  • Mechanism of Action GABA A alpha 5 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Down syndrome; Neurological disorders; Schizophrenia

Most Recent Events

  • 21 Apr 2017 Chemical structure information added
  • 30 Nov 2016 Phase-II clinical trials in Schizophrenia (Adjunctive treatment) in USA (PO) (NCT02953639)
  • 01 Nov 2016 Preclinical trials in Schizophrenia in Switzerland (PO) before November 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top